Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PANOLIV
- Development stage
- Unknown
- Lead developer
- Makshi Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PANOLIV is a branded generic pharmaceutical combination marketed by Makshi Healthcare, primarily used for the management of acid-peptic disorders and gastrointestinal motility issues. It consists of two active ingredients: pantoprazole and levosulpiride. Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cells. Levosulpiride, the levo-enantiomer of sulpiride, acts as a selective antagonist at dopamine D2 receptors, which enhances gastrointestinal motility and accelerates gastric emptying. This combination is typically indicated for conditions such as gastroesophageal reflux disease (GERD), functional dyspepsia, and peptic ulcers, particularly when symptoms are associated with delayed gastric transit.
- Brand names
- PANOLIV
- Other names
- Pantoprazole and LevosulpiridePantoprazole + Levosulpiride
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on PANOLIV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PANOLIV.